https://doi.org/10.55788/a63fa504
The genetic mismatch between natural killer cell immunoglobulin-like receptors (KIRs) and HLA class I molecules has been proposed to be involved in antibody-mediated graft rejection in kidney transplantation. The current study investigated KIR-HLA class I mismatch in a cohort of kidney transplant recipients who did not receive thyroglobulin or rituximab. All recipients underwent KIR genotyping, and all recipients and donors HLA class I genotyping. Per protocol, all graft recipients underwent biopsies at 12- and 36-months following transplant. Microvascular inflammation, composed of glomerulitis and peritubular capillaritis scores was determined for all biopsies. Of all kidney transplant recipients, 23 participants presented with a microvascular inflammation score ≥2 and 57 control participants with a score ≤1 in any biopsy.
Individual mismatch inhibitory KIR-HLA class I interactions did not seem to affect microvascular inflammation scores. However, the proportion of participants with ≥1 inhibitory KIR-HLA class I mismatch was higher in the group with microvascular inflammation scores of ≥2 (73.9%) versus microvascular inflammation scores of ≤1 (50.9%). The participants presenting with microvascular inflammation scores of ≥2 and inhibitory KIR-HLA class I mismatch also showed significantly lower graft survival compared with participants with lower/absent mismatch (P=0.0488). This phenomenon was not observed in patients with activating KIR-HLA class I mismatch. However, overall, more participants with microvascular inflammation scores ≥2 showed total (inhibitory and/or activating) KIR-HLA class I mismatch than participants with low inflammation scores (87% vs 59.7%; P=0.0183). Finally, graft survival was also lower in participants with microvascular inflammation scores of ≥2 and any KIR-HLA class I mismatch (P=0.0278).
“The presence of genetic inhibitory KIR-HLA class I mismatch is more frequent in kidney recipients with microvascular inflammation. Our results support that KIR-HLA class I mismatch favours the development of microvascular inflammation”, concluded Ms Judith Federico-Vega (Hospital del Mar Research Institute, Barcelona, Spain).
- Federico-Vega J, et al. KIR-HLA-I genetic mismatch and the development of antibody-mediated rejection and microvascular inflammation after renal transplantation. Abstract #2461, ERA 2024, 23–26 May, Stockholm, Sweden.
Medical writing support was provided by Mihai Surducan, PhD.
Copyright ©2024 Medicom Medical Publishers
Posted on
Previous Article
« FLOW-trial: Semaglutide improves kidney and cardiovascular outcomes in type 2 diabetes and chronic kidney disease Next Article
TATH trial: Twice-weekly haemodialysis can be an alternative to thrice weekly regimen »
« FLOW-trial: Semaglutide improves kidney and cardiovascular outcomes in type 2 diabetes and chronic kidney disease Next Article
TATH trial: Twice-weekly haemodialysis can be an alternative to thrice weekly regimen »
Table of Contents: ERA 2024
Featured articles
Meet the Experts: Navigating Kidneys and Genes
Chronic Kidney Disease
FLOW-trial: Semaglutide improves kidney and cardiovascular outcomes in type 2 diabetes and chronic kidney disease
Early phase data show albuminuria improvement with avenciguat
Rilparencel leads to kidney function stabilisation in chronic kidney disease and type 2 diabetes
The majority of real-world patients with CKD are not eligible for SGLT2 inhibitor trials
Kidney Transplantation and Dialysis
CD38 inhibition by felzartamab promising for resolution of antibody-mediated rejection following kidney allografts
TATH trial: Twice-weekly haemodialysis can be an alternative to thrice weekly regimen
KIR-HLA class I mismatch could be involved in antibody-mediated rejection of transplanted kidneys
IgA Nephropathy
Atrasentan shows positive interim results in IgA nephropathy: ALIGN phase 3 trial
Zigakibart slows down eGFR decline in IgA nephropathy
Long-term atacicept shows continued benefit in IgA nephropathy
APPLAUSE-IgAN: Iptacopan improves proteinuria in IgA nephropathy
Cardio-Renal Interplay
Semaglutide improves renal outcomes in overweight/obese participants with cardiovascular disease and no diabetes
Discrepancy between cardiovascular RCT participants and real-life CKD patients could limit generalisability of RCT results
MERCURI-1: Perioperative empagliflozin shows renal protection following cardiac surgery
Simulated head-to-head comparison of SGLT-2 inhibitors and GLP-1R agonists in type 2 diabetes
Other Nephrology
Preview of the new KDIGO Guidelines for ADPKD, available later in 2024
APPEAR-C3G: Iptacopan shows promise for complement 3 glomerulopathy
Anti-nephrin autoantibody positivity describes a unique subclass of podocytopathies
Active vitamin D plus low-dose prednisolone is an alternative to high-dose prednisolone in minimal change disease
Claudin-1 is a potential antibody target for crescent glomerulonephritis
Rituximab protocol based on PLA2R1 epitope spreading outperforms the standard GEMRITUX protocol in membranous nephropathy
The REACT score predicts relapse in ANCA-associated vasculitis
Related Articles
June 20, 2024
Zigakibart slows down eGFR decline in IgA nephropathy
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com